Fear of cancer progression in patients with stage IA malignant melanoma
Standard
Fear of cancer progression in patients with stage IA malignant melanoma. / Wagner, Tobias; Augustin, Matthias; Blome, Christine; Forschner, Andrea; Garbe, Claus; Gutzmer, Ralf; Hauschild, Axel; Heinzerling, Lucie; Livingstone, Elisabeth; Loquai, Carmen; Schadendorf, Dirk; Terheyden, Patrick; Mueller-Brenne, Tina; Kähler, Katharina C.
In: EUR J CANCER CARE, Vol. 27, No. 5, 09.2018, p. e12901.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Fear of cancer progression in patients with stage IA malignant melanoma
AU - Wagner, Tobias
AU - Augustin, Matthias
AU - Blome, Christine
AU - Forschner, Andrea
AU - Garbe, Claus
AU - Gutzmer, Ralf
AU - Hauschild, Axel
AU - Heinzerling, Lucie
AU - Livingstone, Elisabeth
AU - Loquai, Carmen
AU - Schadendorf, Dirk
AU - Terheyden, Patrick
AU - Mueller-Brenne, Tina
AU - Kähler, Katharina C
N1 - © 2018 John Wiley & Sons Ltd.
PY - 2018/9
Y1 - 2018/9
N2 - We aimed to determine the prevalence and importance of fear of cancer progression (FoP) in melanoma patients with stage IA tumours to assess psychosocial and demographic factors associated with severity of FoP and to determine the relationship of FoP and quality of life (QoL). One hundred and thirty-six patients with stage IA melanoma completed the short version of the Fear of Progression Questionnaire (FoP-Q-SF), the Hospital Anxiety and Depression Scale (HADS) and the EORTC-QLQ-C30. We found a mean FoP-Q-SF sum score of 30.2 points (±8.4 points SD). In this study, 33% of patients reported high FoP at or above the cutoff-value of 34 points. Higher FoP was found in women (p < 0.01), young (p = 0.03) and employed (p = 0.02) patients. Being confronted with a cancer diagnosis in closely related persons predicted higher FoP (p < 0.01). FoP correlated positively with the HADS anxiety (r = 0.50, p < 0.01) and depression scales (r = 0.26, p < 0.01) and negatively with the EORTC-QLQ-C30 global health state (r = -0.32, p < 0.01). FoP is considerably prevalent in low-risk melanoma patients and associated with reduced QoL, cancer in related persons, women sex and participation in working life. Considerably high levels of FoP, even in patients with low-risk malignancies, underline the need for psychosocial support and psychotherapeutic interventions for melanoma patients.
AB - We aimed to determine the prevalence and importance of fear of cancer progression (FoP) in melanoma patients with stage IA tumours to assess psychosocial and demographic factors associated with severity of FoP and to determine the relationship of FoP and quality of life (QoL). One hundred and thirty-six patients with stage IA melanoma completed the short version of the Fear of Progression Questionnaire (FoP-Q-SF), the Hospital Anxiety and Depression Scale (HADS) and the EORTC-QLQ-C30. We found a mean FoP-Q-SF sum score of 30.2 points (±8.4 points SD). In this study, 33% of patients reported high FoP at or above the cutoff-value of 34 points. Higher FoP was found in women (p < 0.01), young (p = 0.03) and employed (p = 0.02) patients. Being confronted with a cancer diagnosis in closely related persons predicted higher FoP (p < 0.01). FoP correlated positively with the HADS anxiety (r = 0.50, p < 0.01) and depression scales (r = 0.26, p < 0.01) and negatively with the EORTC-QLQ-C30 global health state (r = -0.32, p < 0.01). FoP is considerably prevalent in low-risk melanoma patients and associated with reduced QoL, cancer in related persons, women sex and participation in working life. Considerably high levels of FoP, even in patients with low-risk malignancies, underline the need for psychosocial support and psychotherapeutic interventions for melanoma patients.
KW - Journal Article
U2 - 10.1111/ecc.12901
DO - 10.1111/ecc.12901
M3 - SCORING: Journal article
C2 - 30126009
VL - 27
SP - e12901
JO - EUR J CANCER CARE
JF - EUR J CANCER CARE
SN - 0961-5423
IS - 5
ER -
